眼科臨床試験の市場規模、シェア、動向分析レポート：製品別、フェーズ別、適応症別、スポンサータイプ別、地域別、セグメント予測、2023年～2030年

眼科臨床試験市場の成長と動向

GrandView Research, Inc.の最新レポートによると、世界の眼科臨床試験市場規模は、予測期間中にCAGR 6.6%で2030年までに25億米ドルに達する見込みです。

技術開拓と、より効率的な眼病治療に対するニーズの高まりが、眼科臨床試験市場の急速な拡大を促しています。製薬会社、医療機器メーカー、CRO（医薬品開発業務受託機関）は、この分野の主要な貢献者の一部です。

緑内障、黄斑変性症、糖尿病性網膜症などの眼疾患の罹患率の上昇が業界を牽引しています。世界人口の高齢化が進み、目の病気が一般的になるにつれて、眼科臨床試験市場は今後さらに成長すると予想されます。さらに、遺伝子研究や個別化医療の開発がこの分野の技術革新に拍車をかけ、目の病気に対するより専門的で効率的な治療法が生み出される可能性が高いです。

臨床試験の需要は、眼科研究者が新規眼科用医薬品の開発・販売に注力するようになるため、増加すると思われます。さらに、新興経済諸国における希少な眼疾患に関するアンメットニーズを満たすために採用されているイニシアチブは、眼科臨床試験市場の成長をサポートすると予想されます。例えば、世界保健機関（WHO）が2021年10月に発表した視覚障害者の障害に関する報告書によると、約22億人が分離視や近見視の障害を抱えていると推定され、このうち少なくとも半分の10億例は適切な治療の助けを借りれば回避できるとされています。

COVID-19の大流行は眼科臨床試験市場に大きな影響を与えています。臨床試験は、この流行によって新たな試験の開始が遅れ、患者の登録も遅れています。さらに、いくつかの臨床試験施設が閉鎖を余儀なくされ、患者の訪問やデータ収集が大幅に減少しました。疫病の流行は、遠隔およびバーチャル臨床試験技術の展開を早め、進行中の臨床試験の継続と新たな臨床試験の開始を可能にしました。渡航の制限や社会的隔離の必要性など、パンデミックによってもたらされた困難の一部は、これらの技術を採用することで軽減されています。

眼科臨床試験市場のハイライト

• 2022年には医薬品セグメントが75.5%の最大シェアを占めました。さまざまな眼疾患に対する革新的かつ効率的な薬物療法に対する需要の高まりにより、同分野が市場を独占しています。
• 緑内障分野は、分析期間中に7.3%のCAGRが見込まれています。新規緑内障治療薬開発のための主要企業間の連携やパートナーシップの増加が、同分野の成長に拍車をかけています。
• 臨床段階セグメントは2022年に79.4％の売上シェアで市場を独占しました。臨床試験実施のための民間企業だけでなく、政府別研究開発投資の増加が同分野の成長を牽引しています。
• 2022年の市場は製薬/バイオ製薬企業が41.8%の収益シェアを占めました。眼科臨床試験の主なスポンサーは製薬会社やバイオ製薬会社であり、彼らは新規治療法を開発し商品化するためのリソースと知識を持っているからです。
• アジア太平洋地域は、分析期間中に7.2%の有利なCAGRを記録すると予想されています。これは主に、臨床試験を受けることを希望する患者層が膨大に存在するためです。さらに、インドのような新興国市場における臨床試験の費用対効果の高さは、欧米諸国が臨床研究を行うことをさらに惹きつけ、眼科臨床試験市場における同地域の成長を後押ししています。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
• 地域の範囲
• 推定・予測のタイムライン
• 目的
• 調査手法
• 情報調達
• 情報またはデータ分析
• 市場の形成と検証
• モデル詳細
• 二次情報のリスト
• 略語のリスト

第2章 エグゼクティブサマリー

• 市場の見通し
• セグメントの見通し
• 競合考察

第3章 眼科臨床試験市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/アンシラリー市場見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 眼科臨床試験市場分析ツール
  • 業界分析- ポーターの分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 眼科臨床試験市場：製品推定・動向分析

• 眼科臨床試験市場、製品別：セグメントダッシュボード
• 眼科臨床試験市場、製品別：変動分析
  • デバイス
  • 薬物

第5章 眼科臨床試験市場：適応症の推定・動向分析

• 眼科臨床試験市場、適応症別：セグメントダッシュボード
• 眼科臨床試験市場、適応症別：変動分析
  • 黄斑変性症
  • 緑内障
  • ドライアイ疾患
  • 網膜症
  • ぶどう膜炎
  • 黄斑浮腫
  • 眼瞼炎
  • 白内障
  • 視神経症
  • その他

第6章 眼科臨床試験市場：フェーズの推定・動向分析

• 眼科臨床試験市場、フェーズ別：セグメントダッシュボード
• 眼科臨床試験市場、フェーズ別：変動分析
  • 発見フェーズ
  • 前臨床段階
  • 臨床段階

第7章 眼科臨床試験市場：スポンサータイプの推定・動向分析

• 眼科臨床試験市場、スポンサータイプ別：セグメントダッシュボード
• 眼科臨床試験市場、スポンサータイプ別：変動分析
  • 製薬/バイオ医薬品企業
  • 医療機器企業
  • その他

第8章 眼科臨床試験市場：地域推定・動向分析

• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 北米
  • 市場推計・予測、2018年から2030年（収益）
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • インド
  • 中国
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• MEA
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 市場参入企業の分類
  • イノベーター
  • マーケットリーダー
  • 新興プレイヤー
  • 企業の市場シェア分析、2022年
• 企業プロファイル
  • Charles River Laboratories International, Inc
  • Laboratory Corporation of America Holdings
  • IQVIA
  • ICON Plc
  • Vial
  • Medpace
  • ProTrials Research, Inc.
  • Syneos Health
  • Worldwide Clinical Trials, Inc
  • ProRelix Services LLP.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 North America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
• Table 4 North America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 5 North America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 6 North America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 7 North America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 8 U.S. Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 9 U.S. Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 10 U.S. Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 11 U.S. Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 12 Canada Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 13 Canada Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 14 Canada Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 15 Canada Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 16 Europe Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
• Table 17 Europe Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 18 Europe Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 19 Europe Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 20 Europe Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 21 UK Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 22 UK Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 23 UK Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 24 UK Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 25 Germany Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 26 Germany Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 27 Germany Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 28 Germany Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 29 France Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 30 France Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 31 France Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 32 France Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 33 Italy Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 34 Italy Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 35 Italy Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 36 Italy Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 37 Spain Ophthalmic Clinical Trials market, by Dosage Form type, 2018 - 2030 (USD Million)
• Table 38 Spain Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 39 Spain Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 40 Spain Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 41 Denmark Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 42 Denmark Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 43 Denmark Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 44 Denmark Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 45 Sweden Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 46 Sweden Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 47 Sweden Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 48 Sweden Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 49 Norway Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 50 Norway Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 51 Norway Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 52 Norway Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 58 China Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 59 China Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 60 China Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 61 China Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 62 Japan Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 63 Japan Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 64 Japan Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 65 Japan Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 66 India Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 67 India Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 68 India Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 69 India Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 70 Australia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 71 Australia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 72 Australia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 73 Australia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 74 South Korea Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 75 South Korea Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 76 South Korea Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 77 South Korea Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 78 Thailand Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 79 Thailand Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 80 Thailand Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 81 Thailand Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 82 Latin America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
• Table 83 Latin America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 84 Latin America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 85 Latin America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 86 Latin America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 87 Brazil Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 88 Brazil Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 89 Brazil Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 90 Brazil Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 91 Mexico Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 92 Mexico Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 93 Mexico Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 94 Mexico Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 95 Argentina Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 96 Argentina Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 97 Argentina Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 98 Argentina Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 99 Middle East and Africa Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
• Table 100 Middle East and Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 101 Middle East and Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 102 Middle East and Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 103 Middle East and Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 104 South Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 105 South Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 106 South Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 107 South Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 111 South Arabia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 112 UAE Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 113 UAE Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 114 UAE Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 115 UAE Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
• Table 116 Kuwait Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
• Table 117 Kuwait Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
• Table 118 Kuwait Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
• Table 119 Kuwait Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market research approaches
• Fig. 4 QFD modelling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Primary research pattern
• Fig. 8 Primary interviews in North America
• Fig. 9 Primary interviews in Europe
• Fig. 10 Primary interviews in Asia Pacific
• Fig. 11 Primary interviews in Latin America
• Fig. 12 Primary interviews in MEA
• Fig. 13 Market Snapshot
• Fig. 14 Segment Snapshot
• Fig. 15 Segment Snapshot
• Fig. 16 Competitive Landscape Snapshot
• Fig. 17 Ophthalmic Clinical Trials market segmentation
• Fig. 18 Parent market outlook (2022)
• Fig. 19 Related/ancillary market outlook (2022)
• Fig. 20 Market driver relevance analysis (Current & future impact)
• Fig. 21 Current shared services and outsourcing usage levels
• Fig. 22 Market restraint relevance analysis (Current & future impact)
• Fig. 23 Porter's five forces analysis
• Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
• Fig. 25 Ophthalmic Clinical Trials Market Product outlook: Segment dashboard
• Fig. 26 Ophthalmic Clinical Trials : Product movement analysis
• Fig. 27 Devices market, 2018 - 2030 (USD Million)
• Fig. 28 Drugs market, 2018 - 2030 (USD Million)
• Fig. 29 Ophthalmic Clinical Trials Market Indication outlook: Segment dashboard
• Fig. 30 Ophthalmic Clinical Trials : Indication movement analysis
• Fig. 31 Macular Degeneration market, 2018 - 2030 (USD Million)
• Fig. 32 Glaucoma market, 2018 - 2030 (USD Million)
• Fig. 33 Dry eye diseases market, 2018 - 2030 (USD Million)
• Fig. 34 Retinopathy market, 2018 - 2030 (USD Million)
• Fig. 35 Uveitis market, 2018 - 2030 (USD Million)
• Fig. 36 Macular Edema market, 2018 - 2030 (USD Million)
• Fig. 37 Blepharitis market, 2018 - 2030 (USD Million)
• Fig. 38 Cataract market, 2018 - 2030 (USD Million)
• Fig. 39 Optic neuropathy market, 2018 - 2030 (USD Million)
• Fig. 40 Others market, 2018 - 2030 (USD Million)
• Fig. 41 Ophthalmic Clinical Trials market Phase outlook: Segment dashboard
• Fig. 42 Ophthalmic Clinical Trials market: Phase movement analysis
• Fig. 43 Discovery phase market, 2018 - 2030 (USD Million)
• Fig. 44 Preclinical phase market, 2018 - 2030 (USD Million)
• Fig. 45 Clinical phase market, 2018 - 2030 (USD Million)
• Fig. 46 Ophthalmic Clinical Trials market Sponsor type outlook: Segment dashboard
• Fig. 47 Ophthalmic Clinical Trials market: Sponsor type movement analysis
• Fig. 48 Pharmaceutical/ Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 49 Medical device companies market, 2018 - 2030 (USD Million)
• Fig. 50 Others market, 2018 - 2030 (USD Million)
• Fig. 51 Regional marketplace: Segment dashboard
• Fig. 52 Regional outlook, 2022 & 2030
• Fig. 53 North America market, 2018 - 2030 (USD Million)
• Fig. 54 U.S. market, 2018 - 2030 (USD Million)
• Fig. 55 Canada market, 2018 - 2030 (USD Million)
• Fig. 56 Europe market, 2018 - 2030 (USD Million)
• Fig. 57 Germany market, 2018 - 2030 (USD Million)
• Fig. 58 UK market, 2018 - 2030 (USD Million)
• Fig. 59 France market, 2018 - 2030 (USD Million)
• Fig. 60 Italy market, 2018 - 2030 (USD Million)
• Fig. 61 Spain market, 2018 - 2030 (USD Million)
• Fig. 62 Denmark market, 2018 - 2030(USD Million)
• Fig. 63 Sweden market, 2018 - 2030 (USD Million)
• Fig. 64 Norway market, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market, 2018 - 2030 (USD Million)
• Fig. 66 China market, 2018 - 2030 (USD Million)
• Fig. 67 Japan market, 2018 - 2030 (USD Million)
• Fig. 68 India market, 2018 - 2030 (USD Million)
• Fig. 69 Australia market, 2018 - 2030 (USD Million)
• Fig. 70 South Korea market, 2018 - 2030 (USD Million)
• Fig. 71 Thailand Markey, 2018 - 2030 (USD Million)
• Fig. 71 Latin America market, 2018 - 2030 (USD Million)
• Fig. 72 Brazil market, 2018 - 2030 (USD Million)
• Fig. 73 Mexico market, 2018 - 2030 (USD Million)
• Fig. 74 Argentina market, 2018 - 2030 (USD Million)
• Fig. 75 Middle East & Africa market, 2018 - 2030 (USD Million)
• Fig. 76 South Africa market, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia market, 2018 - 2030 (USD Million)
• Fig. 78 UAE market, 2018 - 2030 (USD Million)
• Fig. 79 Kuwait market, 2018 - 2030 (USD Million)

Ophthalmic Clinical Trials Market Growth & Trends

The global ophthalmic clinical trials market size is expected to reach USD 2.5 billion by 2030 at a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Technological developments and a rising need for more efficient eye disease treatments are driving the market for ophthalmology clinical trials to expand quickly. Pharmaceutical firms, medical equipment producers, and Contract Research Organizations (CROs) are a few of the major contributors to this sector.

The rising incidence of eye conditions, including glaucoma, macular degeneration, and diabetic retinopathy, is driving the industry. As the global population ages and eye illnesses become more common, the market for ophthalmology clinical trials is further anticipated to grow in the coming years. Additionally, developments in genetic research and personalized medicine are likely to spur innovation in this area, creating more specialized and efficient treatments for eye illnesses.

The demand for clinical trials will rise due to the increasing focus of ophthalmic researchers to develop and market novel ocular medicines. Furthermore, the initiatives adopted to fulfill the unmet needs in developing economies regarding rare ocular conditions are anticipated to support the growth of the ophthalmology clinical trials market. For instance, nearly 2.2 billion people are estimated to have separation or close-up vision impairment disorders, and of these, at least half, or 1 billion cases, can be avoided with the aid of appropriate treatment, according to the World Health Organization's October 2021 report on visually impaired people's impairment.

The COVID-19 pandemic has significantly impacted the ophthalmology clinical trials market. Clinical trials have been hampered by the epidemic, which has delayed the start of new trials and slowed patient enrollment. Additionally, several clinical study locations had to close, significantly reducing patient visits and data collecting. The epidemic has hastened the deployment of remote and virtual clinical trial technology, allowing for the continuation of ongoing trials and the start of new ones. Some of the difficulties brought on by the pandemic, including travel limitations and social seclusion requirements, have been mitigated partly by adopting these technologies.

Ophthalmic Clinical Trials Market Highlights

• The drug segment accounted for the largest share of 75.5% in 2022. The segment dominated the market owing to the growing demand for innovative and efficient drug therapies for various eye ailments
• The Glaucoma segment is expected to witness the highest CAGR of 7.3% during the analysis timeframe. The increase in collaboration and partnerships among the key players for developing novel glaucoma products spurs the segment's growth
• The clinical phase segment dominated the market in 2022 with a revenue share of 79.4%. Increasing investments in R&D by the government, as well as private entities for the conduct of clinical studies, drives the segment's growth
• The pharmaceutical/biopharmaceutical companies segment dominated the market in 2022 with a revenue share of 41.8%. The major sponsors of ophthalmology clinical trials are pharmaceutical and biopharmaceutical companies since they have the resources and knowledge to create and commercialize novel treatments
• Asia Pacific is anticipated to register a lucrative CAGR of 7.2% during the analysis period. This is primarily due to a huge patient pool willing to undergo clinical trials. Furthermore, the cost-effective nature of clinical trials across developing economies such as India has further attracted Western countries to conduct clinical research, thereby boosting the region's growth in the ophthalmic clinical trials market

Table of contents

Chapter 1. Research Methodology And Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Product
  • 1.1.3. Indication
  • 1.1.4. Phase
  • 1.1.5. Sponsor Type
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Partnerships Between CROs And Drug Development Companies To Boost The Market Growth
    • 3.2.1.2. Growing Research Funding Pertaining To Ocular Therapeutics Is Another Prominent Factor Supporting The Growth Of The Ophthalmic Clinical Trials Market.
    • 3.2.1.3. Technological Innovations Pertaining to Ophthalmic Research to Boost The Market Growth
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Low Barriers to Market Penetration Have Resulted In Pricing Pressure
    • 3.2.2.2. Challenges Related to Quality Control
• 3.3. Ophthalmic Clinical Trials Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Ophthalmic Clinical Trials Market: Product Estimates & Trend Analysis

• 4.1. Ophthalmic Clinical Trials Market, By Product: Segment Dashboard
• 4.2. Ophthalmic Clinical Trials Market, By Product: Movement Analysis
• 4.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Product, 2018 - 2030
  • 4.3.1. Devices
    • 4.3.1.1. Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.1.2. Surgical & Diagnostics Devices
    • 4.3.1.2.1. Surgical & Diagnostics Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.1.3. Vision Care Devices
    • 4.3.1.3.1. Vision Care Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 4.3.2. Drugs
    • 4.3.2.1. Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.2.2. OTC Drugs
    • 4.3.2.2.1. OTC Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.2.3. Prescription Drugs
    • 4.3.2.3.1. Prescription Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Clinical Trials Market: Indication Estimates & Trend Analysis

• 5.1. Ophthalmic Clinical Trials Market, By Indication: Segment Dashboard
• 5.2. Ophthalmic Clinical Trials Market, By Indication: Movement Analysis
• 5.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 5.3.1. Macular Degeneration
    • 5.3.1.1. Macular Degeneration Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.2. Glaucoma
    • 5.3.2.1. Glaucoma Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.3. Dry Eye Disease
    • 5.3.3.1. Dry Eye Disease Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.4. Retinopathy
    • 5.3.4.1. Retinopathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.5. Uveitis
    • 5.3.5.1. Uveitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.6. Macular Edema
    • 5.3.6.1. Macular Edema Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.7. Blepharitis
    • 5.3.7.1. Blepharitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.8. Cataract
    • 5.3.8.1. Cataract Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.9. Optic Neuropathy
    • 5.3.9.1. Optic Neuropathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.10. Others
    • 5.3.10.1. Others Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Clinical Trials Market: Phase Estimates & Trend Analysis

• 6.1. Ophthalmic Clinical Trials Market, By Phase: Segment Dashboard
• 6.2. Ophthalmic Clinical Trials Market, By Phase: Movement Analysis
• 6.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
  • 6.3.1. Discovery Phase
    • 6.3.1.1. Discovery Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.2. Preclinical Phase
    • 6.3.2.1. Preclinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.3. Clinical Phase
    • 6.3.3.1. Clinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Clinical Trials Market: Sponsor Type Estimates & Trend Analysis

• 7.1. Ophthalmic Clinical Trials Market, By Sponsor Type: Segment Dashboard
• 7.2. Ophthalmic Clinical Trials Market, By Sponsor Type: Movement Analysis
• 7.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
  • 7.3.1. Pharmaceutical/biopharmaceutical Companies
    • 7.3.1.1. Pharmaceutical/biopharmaceutical Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
  • 7.3.2. Medical Device Companies
    • 7.3.2.1. Medical Device Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Others Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 8. Ophthalmic Clinical Trials Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2022 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Competitive Scenario
    • 8.5.1.3. Regulatory Framework
    • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 8.5.2. Germany
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 8.5.3. France
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 8.5.4. Italy
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 8.5.5. Spain
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 8.5.6. Denmark
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 8.5.8. Norway
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Competitive Scenario
    • 8.6.1.3. Regulatory Framework
    • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 8.6.2. India
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 8.6.4. South Korea
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 8.6.6. Thailand
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key Country Dynamics
    • 8.7.1.2. Competitive Scenario
    • 8.7.1.3. Regulatory Framework
    • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 8.7.2. Mexico
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key Country Dynamics
    • 8.8.1.2. Competitive Scenario
    • 8.8.1.3. Regulatory Framework
    • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 8.8.3. UAE
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 8.8.4. Kuwait
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Innovators
  • 9.1.2. Market Leaders
  • 9.1.3. Emerging Players
  • 9.1.4. Company Market Share Analysis, 2022
• 9.2. Company Profiles
  • 9.2.1. Charles River Laboratories International, Inc
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Service Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Laboratory Corporation of America Holdings
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Service Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. IQVIA
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Service Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. ICON Plc
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Service Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Vial
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Service Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Medpace
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Service Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. ProTrials Research, Inc.
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Service Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Syneos Health
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Service Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. Worldwide Clinical Trials, Inc
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Service Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. ProRelix Services LLP.
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Service Benchmarking
    • 9.2.10.4. Strategic Initiatives